Navigation Links
Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:3/1/2012

REDWOOD CITY, Calif., March 1, 2012 /PRNewswire/ -- Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today that Alan Levy, PhD, Chief Executive Officer, and David Socks, President and Chief Operating Officer, will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:00a.m. Eastern Time at the Boston Marriott Copley Place.

About Incline Therapeutics, Inc.
Incline Therapeutics is a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system), a compact, disposable, needleless patient-controlled system for the short-term management of acute postoperative pain in adult patients requiring opioid analgesia during hospitalization.  IONSYS has completed Phase III development and was previously approved in the United States and Europe.  Prior to marketing IONSYS, Incline must seek approval of a supplement New Drug Application (sNDA) in the United States and a Marketing Authorization Application (MAA) in Europe.  Incline is financed by leading life science venture capital firms and led by a management team with significant pharmaceutical and medical device industry experience.  The company is based in Redwood City, California.

Incline™ and IONSYS™ are trademarks of Incline Therapeutics, Inc.


'/>"/>
SOURCE Incline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Orexigen Therapeutics to Present at Upcoming Conferences
4. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
5. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
6. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
7. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
8. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
11. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):